VION Biosciences Acquires Echelon Biosciences

VION Biosciences Acquires Ansh Labs

August 29, 2024

Biotechnology

VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Ansh Labs, an immunoassay development and reagent manufacturer based in Houston, Texas. The add-on expands VION's diagnostics capabilities — adding GMP IVD manufacturing and ISO 13485 certification — and broadens the platform's product and service offerings for clinical diagnostics, research, and pharmaceutical development.

Iron Path Capital-backed VION Biosciences Acquires Aldon Corporation

August 7, 2023

Manufacturing

Iron Path Capital has formed VION Biosciences as a life-science roll-up platform and completed the acquisition of Aldon Corporation, a private-label manufacturer and distributor of lab chemicals headquartered in Avon, New York. Aldon will serve as VION’s inaugural platform investment to build a specialty chemicals and reagents business serving biopharma, molecular diagnostics and STEM education markets; Mark Thornton was named CEO of VION Biosciences.

VION Biosciences Acquires BioAssay Systems

February 5, 2025

Biotechnology

VION Biosciences acquired Hayward, California–based BioAssay Systems in January 2025 as the fourth add-on for its life‑science products platform. The deal adds BioAssay Systems’ enzymatic and high‑throughput assay kits, reagents and analytical services to VION’s proprietary product portfolio to accelerate capability expansion for drug discovery and life‑science research customers.

Agilent Technologies Acquires e-MSion

March 9, 2023

Medical Devices

Agilent Technologies has acquired e-MSion, the early-stage company behind the ExD cell electron capture dissociation (ECD) technology for benchtop mass spectrometers. The purchase brings e-MSion's ExD cell and associated tools into Agilent's life-sciences instrument portfolio to expand biopharma characterization capabilities and make ECD accessible to a broader set of labs.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Bruker Corporation Acquires Nion

January 3, 2024

Manufacturing

Bruker Corporation has acquired Nion, a Kirkland, Washington developer and manufacturer of high-end scanning transmission electron microscopes (STEM), including the UltraSTEM line and advanced EELS technology. The acquisition strengthens Bruker's materials science instrumentation portfolio and provides capabilities for electron diffraction crystallography; Nion reported approximately $8 million in revenue in 2023. Financial terms were not disclosed.